Compare Dr. Reddys with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ORCHID PHARMA LTD - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ORCHID PHARMA LTD DR. REDDYS LAB/
ORCHID PHARMA LTD
 
P/E (TTM) x 21.5 -0.5 - View Chart
P/BV x 3.2 0.1 2,735.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs2,875194 1,482.0%   
Low Rs1,88835 5,394.3%   
Sales per share (Unadj.) Rs930.2276.5 336.5%  
Earnings per share (Unadj.) Rs117.4-79.2 -148.2%  
Cash flow per share (Unadj.) Rs185.8-43.5 -427.5%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.453.9 1,565.6%  
Shares outstanding (eoy) m166.0770.45 235.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.60.4 618.2%   
Avg P/E ratio x20.3-1.4 -1,403.1%  
P/CF ratio (eoy) x12.8-2.6 -486.5%  
Price / Book Value ratio x2.82.1 132.9%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4968,067 4,902.9%   
No. of employees `00022.02.8 784.5%   
Total wages/salary Rs m33,5622,527 1,328.1%   
Avg. sales/employee Rs Th7,032.86,956.1 101.1%   
Avg. wages/employee Rs Th1,527.9902.5 169.3%   
Avg. net profit/employee Rs Th887.7-1,993.0 -44.5%   
INCOME DATA
Net Sales Rs m154,48219,477 793.2%  
Other income Rs m3,375407 828.8%   
Total revenues Rs m157,85719,884 793.9%   
Gross profit Rs m31,7821,103 2,882.5%  
Depreciation Rs m11,3482,519 450.5%   
Interest Rs m8895,227 17.0%   
Profit before tax Rs m22,920-6,236 -367.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m3,858-125 -3,081.5%   
Profit after tax Rs m19,500-5,580 -349.4%  
Gross profit margin %20.65.7 363.4%  
Effective tax rate %16.82.0 838.4%   
Net profit margin %12.6-28.7 -44.1%  
BALANCE SHEET DATA
Current assets Rs m111,10111,014 1,008.7%   
Current liabilities Rs m58,97332,060 183.9%   
Net working cap to sales %33.7-108.1 -31.2%  
Current ratio x1.90.3 548.4%  
Inventory Days Days7995 83.6%  
Debtors Days Days9434 280.7%  
Net fixed assets Rs m101,24529,440 343.9%   
Share capital Rs m830705 117.8%   
"Free" reserves Rs m139,4062,043 6,824.9%   
Net worth Rs m140,2363,800 3,690.5%   
Long term debt Rs m22,0009,018 244.0%   
Total assets Rs m224,65646,510 483.0%  
Interest coverage x26.8-0.2 -13,867.9%   
Debt to equity ratio x0.22.4 6.6%  
Sales to assets ratio x0.70.4 164.2%   
Return on assets %9.1-0.8 -1,194.1%  
Return on equity %13.9-146.9 -9.5%  
Return on capital %14.9-3.7 -400.2%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m88,6737,513 1,180.2%   
Fx outflow Rs m19,1045,649 338.2%   
Net fx Rs m69,5691,865 3,731.2%   
CASH FLOW
From Operations Rs m28,7041,682 1,706.8%  
From Investments Rs m-7,727-9,860 78.4%  
From Financial Activity Rs m-21,3266,644 -321.0%  
Net Cashflow Rs m-314-1,535 20.5%  

Share Holding

Indian Promoters % 25.5 32.3 78.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.6 117.4%  
FIIs % 35.3 3.3 1,069.7%  
ADR/GDR % 18.5 4.6 402.2%  
Free float % 15.3 55.3 27.7%  
Shareholders   75,885 84,811 89.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  SHASUN PHARMA  GSK PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 17, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - PFIZER COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS